Literature DB >> 17098527

Resource utilization in the treatment of critical limb ischemia: The effect of tissue loss, comorbidities, and graft-related events.

Louis L Nguyen1, Stuart R Lipsitz, Dennis F Bandyk, Alexander W Clowes, Gregory L Moneta, Michael Belkin, Michael S Conte.   

Abstract

OBJECTIVE: Resource utilization (RU) in the care of patients with critical limb ischemia (CLI) is not well quantified. We present a cohort study to quantify in-hospital RU and analyze the role of tissue loss (TL), comorbidities, and vascular graft-related events (GREs) in patients undergoing peripheral bypass for CLI.
METHODS: A retrospective analysis of 1404 patients enrolled in a multicenter clinical trial (PREVENT III) of vein bypass grafting for CLI was performed with analysis of RU during the 1-year follow-up period. Univariate and multivariable linear regressions were performed to determine RU predictors and outcomes.
RESULTS: Compared with patients with rest pain, patients presenting with TL as the indication for bypass surgery had a longer index length of stay (mean, 9.8 vs 6.2 days), more rehospitalizations (mean, 1.6 vs 1.2), and a longer cumulative length of stay (mean, 27.7 vs 17.3 days; P < .0001 for all comparisons). Rehospitalizations over the ensuing year were for additional procedures (37.5%), wound infection (14.6%), graft failure (10.7%), and other cardiovascular (10%) and noncardiovascular (26%) reasons. Early GRE (stenosis > or =70%, thrombosis, revision, or major amputation within 30 days) occurred in 162 (11.5%) patients, resulting in a longer index length of stay (mean, 11.8 vs 8.6 days; P = .0002) and cumulative length of stay (mean, 25.9 vs 24.6 days; P = .0043), but no difference in the number of rehospitalizations (mean, 1.6 vs 1.5 days; P = .3272). During the 1-year follow-up, 554 (39.5%) patients had GREs, and this resulted in more rehospitalizations (mean, 2.1 vs 1.1; P < .0001) and a longer cumulative length of stay (mean, 28.2 vs 21.9 days; P < .0001) compared with patients without GRE. Multivariable analysis demonstrated the highly positive association of TL (hazard ratio [HR], 1.75) and early GRE (HR, 1.77) with the index length of stay, whereas comorbidities-namely, dialysis dependency (HR, 1.31), nonsmoking status (HR, 1.29), hypertension (HR, 1.26), and increasing age (HR, 1.01)-also had strong effects. The effect of TL and GRE on later RU (number of rehospitalizations and cumulative length of stay) was present but less pronounced than patient comorbidities (namely, dialysis).
CONCLUSIONS: The stage of disease at presentation (TL vs rest pain) and the patency of the bypass graft (freedom from GRE) are critical determinants of RU over the first year after limb-salvage surgery. These effects predominate early (index length of stay) and persist through 1 year. Patient-specific factors, particularly dialysis-dependent renal failure, are also critical comorbidities affecting RU in these patients.

Entities:  

Mesh:

Year:  2006        PMID: 17098527     DOI: 10.1016/j.jvs.2006.07.035

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  9 in total

Review 1.  Disparities in vascular surgery: is it biology or environment?

Authors:  Louis L Nguyen; Antonia J Henry
Journal:  J Vasc Surg       Date:  2010-04       Impact factor: 4.268

2.  Relationship between regional spending on vascular care and amputation rate.

Authors:  Philip P Goodney; Lori L Travis; Benjamin S Brooke; Randall R DeMartino; David C Goodman; Elliott S Fisher; John D Birkmeyer
Journal:  JAMA Surg       Date:  2014-01       Impact factor: 14.766

3.  Clinical factors that influence the cellular responses of saphenous veins used for arterial bypass.

Authors:  Michael Sobel; Shinsuke Kikuchi; Lihua Chen; Gale L Tang; Tom N Wight; Richard D Kenagy
Journal:  J Vasc Surg       Date:  2018-06-15       Impact factor: 4.268

Review 4.  Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications.

Authors:  Christopher D Owens
Journal:  J Vasc Surg       Date:  2009-10-17       Impact factor: 4.268

5.  Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia.

Authors:  Louis L Nguyen; Soma Brahmanandam; Dennis F Bandyk; Michael Belkin; Alexander W Clowes; Gregory L Moneta; Michael S Conte
Journal:  J Vasc Surg       Date:  2007-12       Impact factor: 4.268

6.  Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss.

Authors:  Louis L Nguyen; Nathanael Hevelone; Selwyn O Rogers; Dennis F Bandyk; Alexander W Clowes; Gregory L Moneta; Stuart Lipsitz; Michael S Conte
Journal:  Circulation       Date:  2008-12-22       Impact factor: 29.690

7.  Perfusion Assessment in Critical Limb Ischemia: Principles for Understanding and the Development of Evidence and Evaluation of Devices: A Scientific Statement From the American Heart Association.

Authors:  Sanjay Misra; Mehdi H Shishehbor; Edwin A Takahashi; Herbert D Aronow; Luke P Brewster; Matthew C Bunte; Esther S H Kim; Jonathan R Lindner; Kathleen Rich
Journal:  Circulation       Date:  2019-08-12       Impact factor: 29.690

8.  The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design.

Authors:  Eric Benoit; Thomas F O'Donnell; Mark D Iafrati; Enrico Asher; Dennis F Bandyk; John W Hallett; Alan B Lumsden; Gregory J Pearl; Sean P Roddy; Krishnaswami Vijayaraghavan; Amit N Patel
Journal:  J Transl Med       Date:  2011-09-27       Impact factor: 5.531

9.  Combined autologous bone marrow mononuclear cell and gene therapy as the last resort for patients with critical limb ischemia.

Authors:  Jan Skóra; Artur Pupka; Dariusz Janczak; Piotr Barć; Tomasz Dawiskiba; Krzysztof Korta; Dagmara Baczyńska; Agnieszka Mastalerz-Migas; Jerzy Garcarek
Journal:  Arch Med Sci       Date:  2014-07-23       Impact factor: 3.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.